/stocks — the workspaceLOADING
Royalty Pharma plc (RPRX) is a pharmaceutical preparations company. Piotroski F-Score 4/7. 22 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-08-05 from RPRX's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
FY ending 2025-12-31 vs 2024-12-31.
A plain-English read on RPRX plus an auto-SWOT — built from RPRX's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate RPRX using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Dorsey Asset Management (Pat Dorsey) | $109.2M | 8.7% of portfolio |
| Hite ChristopherEVP & Chairman, Partnering | SELL | $7.3M | view → |
| Urist MarshallEVP, Research & Investments | SELL | $508K | view → |
| Hite ChristopherEVP & Chairman, Partnering | SELL | $8.2M | view → |
| Urist MarshallEVP, Research & Investments | SELL | $502K | view → |
| Coyne Terrance P.EVP & CFO | SELL | $3.5M | view → |
| Urist MarshallEVP, Research & Investments | SELL | $722K | view → |
| Norden GregoryDirector | SELL | $161K | view → |
| Urist MarshallEVP, Research & Investments | SELL | $726K | view → |
Projected from RPRX's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment RPRX files its announcement.
RPRX has rallied after 5 of its last 8 earnings reports.
Each figure is one earnings reaction — how much RPRX moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Earnings reactions have been moderate.
RPRX has traded higher after most recent earnings releases.
The average is inflated by its most volatile prints (+14.5% and -3.7%).
A more typical earnings reaction has been approximately ±2.2%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-05-06 | -0.5% |
| 2026-02-11 | +1.3% |
| 2025-11-05 | +7.8% |
| 2025-08-06 | -2.4% |
| 2025-05-08 | +1.2% |
| 2025-02-11 | +2.0% |
| 2025-01-10 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| +14.5% |
| 2024-11-06 | -3.7% |